A new study recently published in the Journal of Neuroscience has revealed how memory and abnormal brain activity are linked in people with epilepsy.
Memory impairment or loss is a common complaint amongst people with epilepsy and this study, which was conducted by Cedars-Sinai in the US, investigated the area of the brain which is key to memory –the hippocampus.
A major new study recently published in the New England Journal of Medicine has stated that levetiracetam (Keppra), fosphenytoin (Pro-Epanutin) and valproate (Epilim) are equally effective in the treatment of Status Epilepticus.
The international study featured collaboration between a number of institutions in the UK & the US and sought to establish whether the drugs stated above are effective in the treatment of Status Epilepticus.
A new study undertaken by a number of institutions in the United States and recently published in the journal, JAMA Neurology , has recommended that mothers with epilepsy continue to breastfeed as normal despite being on epilepsy medication.
Epilepsy Ireland have received a request from DCU PHD student ,Orla Mooney seeking participants for the Awesme Study - Adolesecents With Epilepsy Self Management Experiences. Orla has outlined the goals of the study below and what is involved for potential participants.
We receive research requests and those that are looking for volunteers can be found in the research section of our website.
Epilepsy Ireland can officially confirm that the Peaks Challenge 2020 will take place on the weekend of the 4th July.
The annual challenge see’s participants put their bodies to the test by taking on the four Peaks of Tonelagee, Lugnaquillia, Luggala & the Blackstairs Mountains.
The Peaks costs €575 per person however deposits are now being taken for an early bird rate of €525, which will only apply until January 15th.
Further to our recent news items towards the tail-end of 2019 regarding the supply of Gabitril 5mg, 10mg & 15mg, we can confirm that the supply issues experienced have now been resolved following further communication from the drug's manufacturer TEVA.
Furthermore, the HPRA have confirmed that delivery received should be enough to meet patient demand for all of 2020 and therefore no further supply issues are envisaged for the upcoming year.